VC-backed Antibes Therapeutics completes IPO
Toronto-based Antibe Therapeutics Inc. (TSX VENTURE:ATE), a developer of pharmaceuticals focused on diseases characterized by inflammation, pain and vascular dysfunction, has completed the final tranche of its initial public offering on the TSX Venture Exchange. Proceeds of $3 million were raised in total. Founded in 2004, the company has been backed by several private investors, including Canadian early stage venture capital firm Hero Ventures, which invested in Antibe in 2008.
24 August 2013•4 mins read
